UCHL1 and Parkinson disease: In vitro, 1-(3,4-dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline, an endogenous parkinsonism-inducing dopamine derivative, binds to UCHL1 specifically at Cys152.